Psoriasis trials recruiting in Texas

All Psoriasis trials nationally

Cities in Texas

Recruiting trials in Texas

• A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
  NCT07250802 · Phase: Phase 3 · Ages: 4 Years to 17 Years · Sex: All (male and female) · Texas: Bellaire, San Antonio
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
  NCT06671483 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Baytown, Bellaire, Houston, Lubbock
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
  NCT06671496 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Fort Worth, Houston, The Woodlands
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
  NCT06100744 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Texas: Austin
• A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
  NCT07801495 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Texas: San Antonio
• A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
  NCT07489885 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Texas: San Antonio
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
  NCT06807424 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Frisco, Harlingen, Irving
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
  NCT07321873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Frisco
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
  NCT06979453 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Texas: San Antonio, Southlake
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Colleyville, Fort Worth, Houston, Irving
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Bellaire, Dallas, Houston, Pflugerville
• A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
  NCT07290036 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Baytown, Colleyville, Mesquite, Plano
• An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
  NCT07449702 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Frisco, Houston, Webster
• Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
  NCT07286058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Baytown, Bellaire, Houston, Lubbock
• Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
  NCT07280702 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Texas: Dallas
• Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
  NCT07474792 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Texas: Dallas, Houston, Webster
• Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
  NCT06641089 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Allen, Austin, Baytown, Colleyville
• Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
  NCT05669833 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Texas: Colleyville, El Paso
• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
  NCT07116967 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · Texas: Arlington, Cypress, Dallas, Houston
• Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
  NCT02418442 · Phase: Not specified · Ages: Up to 21 Years · Sex: All (male and female) · Texas: Dallas, Houston
• Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
  NCT06982352 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
  NCT06865105 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Houston, San Antonio, Tomball
• Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
  NCT07486960 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Texas: Houston
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Fort Worth, Houston, Richardson
• Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
  NCT04751396 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston